Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



聯康集團
Uni-Bio Science

UNI-BIO SCIENCE GROUP LIMITED

聯康生物科技集團有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 0690)

PROPOSED TERMINATION OF THE EXISTING SHARE OPTION SCHEME AND ADOPTION OF THE NEW SHARE OPTION SCHEME

The Board of the Company is pleased to announce that, the Board has proposed (i) the termination of the Existing Share Option Scheme and (ii) adoption of the New Share Option Scheme for the approval by the Shareholders.

The Existing Share Option Scheme, which was adopted by the Shareholders at the annual general meeting of the Company on 26 September 2016, will expire in September 2026 and no further options can be granted thereunder. As at the date of this announcement, a total 420,589,000 options granted under the Existing Share Option Scheme were outstanding. In view of the expiration of the Existing Share Option Scheme and in order to continue to enable the Directors to provide appropriate rewards to suitable and eligible persons for their contribution or potential contribution to the Group, the Board proposes to adopt the New Share Option Scheme in accordance with Chapter 17 of the Listing Rules.

The adoption of the New Share Option Scheme is conditional upon:

(1) the Stock Exchange granting approval for the listing of and permission to deal in such number of Shares representing the scheme mandate limit (being such number representing 10% of the number of the issued Shares as at the date of the EGM); and

(2) the passing of the necessary resolution at the EGM to approve the adoption of the New Share Option Scheme and to authorise the Directors to grant options under the New Share Option Scheme and to allot and issue Shares pursuant to the exercise of any options granted.

* *For identification purposes only*

The EGM will be convened for the Shareholders to consider and, if thought fit, pass the ordinary resolution to approve the proposed termination of the Existing Share Option Scheme, the adoption of the New Share Option Scheme, and the approval of the service provider sublimit.

A circular containing, among other things, details of the New Share Option Scheme; and a notice convening the EGM, is expected to be published on 28 April 2026.

DEFINITIONS

Terms or expressions used in this announcement shall, unless the context otherwise requires, have the meanings ascribed to them below:

"Board"	the board of Directors
"Company"	Uni-Bio Science Group Limited 聯康生物科技集團有限公司*, a company incorporated in the Cayman Islands with limited liability and the issued Shares of which are listed on Stock Exchange
"Director(s)"	the director(s) of the Company
"EGM"	the extraordinary general meeting of the Company to be convened and held to consider and, if thought fit, approve, termination of the Existing Share Option Scheme, the adoption of the New Share Option Scheme, and the approval of the service provider sublimit
"Existing Share Option Scheme"	the existing share option scheme of the Company adopted by the Company on 26 September 2016
"Group"	the Company and its subsidiaries
"Listing Rules"	the Rules Governing the Listing of Securities on the Stock Exchange
"New Share Option Scheme"	the new share option scheme proposed to be adopted by the Company at the EGM
"Share(s)"	ordinary share(s) of HK$0.01 each in the share capital of the Company

''Shareholder(s)''	holder(s) of the Share(s)
''Stock Exchange''	The Stock Exchange of Hong Kong Limited

On behalf of the Board
Uni-Bio Science Group Limited
Kingsley Leung
Chairman

Hong Kong, 23 April 2026

As at the date of this announcement, the Board comprises four executive Directors, namely, Mr. Kingsley Leung (Chairman), Mr. Chen Dawei (Vice-Chairman), Mr. Zhao Zhi Gang (Chief executive) and Dr. Wen Yalei (Chief Operating Officer); two non-executive Directors, Mr. Yau Kwok Wing Tony and Ms. Zhang Qing; and three independent non-executive Directors, namely, Mr. Chow Kai Ming, Mr. Ren Qimin and Mr. Ma Qingshan.

* *For identification purposes only*